Skip to main content
SpringerLink
Log in

Conclusions

  • Conclusions
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. Anidulafungin is a well tolerated echinocandin with a favorable pharmacokinetic profile; in particular, its lack of hepatic metabolism and renal excretion enables drug administration without dosage adjustment to subjects with any degree of impaired hepatic or renal function. This simplifies dosing, with a requirement for only once-daily administration and a lack of drug-drug interactions in patients who require multiple medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

]References

  1. Garber G. An overview of fungal infections. Drugs 2001; 61 Suppl.1: 1–12

    Article  Google Scholar 

  2. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United State Hospitals: a three year analysis. Clinic Infect Dis 1999; 29: 239–44

    Article  CAS  Google Scholar 

  3. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317–22

    Article  PubMed  CAS  Google Scholar 

  4. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3(11): 685–702

    Article  PubMed  Google Scholar 

  5. Brielmaier BD, Casabar E, Kutzeborn CM, et al. Early clinical experience with anidulafungin at a large tertiary care medical centre. Pharmacother 2008; 28(1): 64–73

    Article  CAS  Google Scholar 

  6. Castagnola E, Buratti S. Clinical aspects of invasive candidiasis in paediatric patients. Drugs 2009; 69 Suppl.1: 45–50

    Article  Google Scholar 

  7. Cauda R. Candidaemia in patients with an inserted medical device. Drugs 2009; 69 Suppl.1: 33–8

    Article  Google Scholar 

  8. Concia E, Azzini AM, Conti M. Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients. Drugs 2009; 69 Suppl.1: 5–14

    Article  Google Scholar 

  9. Grossi PA. Clinical aspects of invasive candidiasis in solid organ transplant recipients. Drugs 2009; 69 Suppl.1: 15–20

    Article  Google Scholar 

  10. Gullo A. Invasive fungal infections: the challenge continues. Drugs 2009; 69 Suppl.1: 65–73

    Article  Google Scholar 

  11. Mazzei T, Novelli A. Pharmacological properties of anti-fugnal drugs with a focus on anidulafungin. Drugs 2009; 69 Suppl.1: 79–90

    Article  Google Scholar 

  12. Menichetti F. Anidulafungin, a new echinocandin: effectiveness and tolerability. Drugs 2009; 69 Suppl.1: 95–7

    Article  Google Scholar 

  13. Montagna MT, Caggiano G, Borghi E, et al. The role of the laboratory in the diagnosis of invasive candidiasis. Drugs 2009; 69 Suppl.1: 59–63

    Article  Google Scholar 

  14. Morace G, Borghi E, Iatta R. Anidulafungin, a new echinocandin: in vitro activity. Drugs 2009; 69 Suppl.1: 91–4

    Article  Google Scholar 

  15. Pennisi M, Antonelli M. Clinical aspects of invasive candidiasis in critically ill patients. Drugs 2009; 69 Suppl.1: 21–8

    Article  Google Scholar 

  16. Sganga G. Clinical aspects of invasive candidiasis in the surgical patient. Drugs 2009; 69 Suppl.1: 29–32

    Article  Google Scholar 

  17. Venditti M. Clinical aspects of invasive candidiasis: endocarditis and other localized infections. Drugs 2009; 69 Suppl.1: 39–43

    Article  Google Scholar 

  18. Viale P. Candida colonization and candiduria in critically ill patients in the intensive care unit. Drugs 2009; 69 Suppl.1: 51–7

    Article  Google Scholar 

  19. Viscoli C. Antifungal prophylaxis and pre-emptive therapy. Drugs 2009; 69 Suppl.1: 75–8

    Article  Google Scholar 

  20. Dowell JA, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44: 590–8

    Article  PubMed  CAS  Google Scholar 

  21. Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227–33

    Article  PubMed  CAS  Google Scholar 

  22. Dowell JA, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47: 461

    Article  PubMed  CAS  Google Scholar 

  23. Vasquez JA, et al. The safety of anidulafungin. Expert Opin Drug Safety 2006; 5(6): 751–8

    Article  Google Scholar 

  24. Reboli AC, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356(24): 2472–82

    Article  PubMed  CAS  Google Scholar 

  25. Vazquez JA, et al. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215–22

    Article  PubMed  Google Scholar 

  26. Vazquez JA, Schranz JA, Clark K, et al. A phase-2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008; 48(3): 304–9

    Article  PubMed  CAS  Google Scholar 

  27. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46(1): 150–6

    CAS  Google Scholar 

  28. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin and micafungin: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2008; 46(8): 2620–9

    Article  PubMed  CAS  Google Scholar 

  29. Infectious disease community of practice, fungal infections. Am J Transplant 2004; 4 Suppl. 10: 110–34

    Article  Google Scholar 

  30. Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogenic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006; 4(3): 457–68

    Article  PubMed  CAS  Google Scholar 

  31. Bhatti Z, Shaukat A, Almyroudis NG, et al. Review of epidemiology diagnosis and treatment of invasive mould infections in allogenic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162: 1–15

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author would like to thank Raelene Simpson of Wolters Kluwer Pharma Solutions who provided assistance with English language editing. This assistance was funded by Pfizer. The author has no conflicts of interest to declare.

Professor De Bellis passed away soon after contributing this article. Final revisions of the article were therefore completed by Claudio Viscoli on behalf of the author.

Author information

Authors and Affiliations

  1. UOC Institute of Anesthesia and Resuscitation, Department of Cardiac-Nephrology, Azienda Ospedaliera Universitaria S. Martino di Genova, Genoa, Italy

    Pasquale De Bellis

Authors
  1. Pasquale De Bellis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Bellis, P. Conclusions. Drugs 69 (Suppl 1), 99–102 (2009). https://doi.org/10.2165/11315580-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11315580-000000000-00000

Keywords

Search

Navigation